Nkarta (NKTX) Net Income (2019 - 2026)
Nkarta (NKTX) posted quarterly Net Income of -$34.0 million for Q1 2026, up 9.81% year-over-year from -$31.0 million in Q1 2025, and down 0.85% quarter-over-quarter from -$33.8 million in Q4 2025.
Nkarta (NKTX) Net Income (2019 - 2026) Analysis & Trends
Nkarta's Net Income history runs 8 years deep, the most recent figure standing at -$34.0 million for Q1 2026.
- In Q1 2026, Net Income rose 9.81% year-over-year to -$34.0 million; the TTM figure through Mar 2026 stood at -$190.5 million (down 42.28% YoY), while the FY2025 annual figure was -$257.9 million, down 99.55% from the prior year.
- Net Income for Q1 2026 stood at -$34.0 million, down from -$33.8 million in the prior quarter.
- The five-year high for Net Income was -$26.6 million in Q1 2022, with the low at -$180.2 million in Q2 2023.
- The 5-year median for Net Income is -$37.7 million (2025), against an average of -$65.4 million.
- The sharpest annual moves came in 2022 and 2024: Net Income tumbled 514.86% in 2022, then surged 82.94% in 2024.
- Nkarta's Net Income stood at -$36.1 million in 2022, then retreated by 20.49% to -$43.5 million in 2023, then advanced by 29.15% to -$30.8 million in 2024, then dropped by 9.58% to -$33.8 million in 2025, then retreated by 0.85% to -$34.0 million in 2026.
- Business Quant data shows NKTX's Net Income at -$34.0 million in Q1 2026, -$33.8 million in Q4 2025, and -$60.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Nkarta | 201.14 Mn | 201.14 Mn | - | -46.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -145.95 Mn |
| Mar 31, 2026 | -34.04 Mn |
| Dec 31, 2025 | -33.75 Mn |
| Sep 30, 2025 | -60.52 Mn |
| Jun 30, 2025 | -62.15 Mn |
| Mar 31, 2025 | -37.74 Mn |
| Dec 31, 2024 | -30.80 Mn |
| Sep 30, 2024 | -34.57 Mn |
| Jun 30, 2024 | -30.75 Mn |
| Mar 31, 2024 | -60.42 Mn |
| Dec 31, 2023 | -43.47 Mn |
| Sep 30, 2023 | -169.42 Mn |
| Jun 30, 2023 | -180.22 Mn |
| Mar 31, 2023 | -36.65 Mn |
| Dec 31, 2022 | -36.08 Mn |
| Sep 30, 2022 | -88.41 Mn |
| Jun 30, 2022 | -145.81 Mn |
| Mar 31, 2022 | -26.59 Mn |
| Dec 31, 2021 | -23.97 Mn |
| Sep 30, 2021 | -39.69 Mn |